Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

pSTAT3 Levels Have Divergent Expression Patterns and Associations with Survival in Squamous Cell Carcinoma and Adenocarcinoma of the Oesophagus.

O' Sullivan KE, Michielsen AJ, O' Regan E, Cathcart MC, Moore G, Breen E, Segurado R, Reynolds JV, Lysaght J, O' Sullivan J.

Int J Mol Sci. 2018 Jun 10;19(6). pii: E1720. doi: 10.3390/ijms19061720.

2.

Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.

Melo AM, Zhang L, Dockry ÉF, Petrasca A, Ghnewa YG, Breen EP, Morrissey ME, O'Reilly C, Bruen R, O'Meara A, Lysaght J, Zhu X, Doherty DG.

Glycobiology. 2018 Jul 1;28(7):512-521. doi: 10.1093/glycob/cwy035.

PMID:
29688330
3.

Human dorsal root ganglion pulsed radiofrequency treatment modulates cerebrospinal fluid lymphocytes and neuroinflammatory markers in chronic radicular pain.

Das B, Conroy M, Moore D, Lysaght J, McCrory C.

Brain Behav Immun. 2018 May;70:157-165. doi: 10.1016/j.bbi.2018.02.010. Epub 2018 Feb 16.

PMID:
29458195
4.

Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.

Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J.

Cancer Lett. 2018 Apr 1;418:230-238. doi: 10.1016/j.canlet.2018.01.039. Epub 2018 Jan 12.

PMID:
29339209
5.

Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1.

Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, Horne MK.

J Biol Chem. 2017 Jul 14;292(28):12007. doi: 10.1074/jbc.A117.603393. No abstract available.

6.

Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma.

Doyle SL, Mongan AM, Donohoe CL, Pidgeon GP, Sherlock M, Reynolds JV, Lysaght J.

Dis Esophagus. 2017 Jun 1;30(6):1-11. doi: 10.1093/dote/dox008.

PMID:
28475745
7.

Emerging Concepts Linking Obesity with the Hallmarks of Cancer.

Donohoe CL, Lysaght J, O'Sullivan J, Reynolds JV.

Trends Endocrinol Metab. 2017 Jan;28(1):46-62. doi: 10.1016/j.tem.2016.08.004. Epub 2016 Sep 12. Review.

PMID:
27633129
8.

Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.

Cathcart MC, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, O'Byrne KJ, Pidgeon GP.

BMC Cancer. 2016 Sep 1;16:707. doi: 10.1186/s12885-016-2740-0.

9.

Parallel Profiles of Inflammatory and Effector Memory T Cells in Visceral Fat and Liver of Obesity-Associated Cancer Patients.

Conroy MJ, Galvin KC, Doyle SL, Kavanagh ME, Mongan AM, Cannon A, Moore GY, Reynolds JV, Lysaght J.

Inflammation. 2016 Oct;39(5):1729-36. doi: 10.1007/s10753-016-0407-2.

PMID:
27423204
10.

The microenvironment of visceral adipose tissue and liver alter natural killer cell viability and function.

Conroy MJ, Fitzgerald V, Doyle SL, Channon S, Useckaite Z, Gilmartin N, O'Farrelly C, Ravi N, Reynolds JV, Lysaght J.

J Leukoc Biol. 2016 Dec;100(6):1435-1442. Epub 2016 Jun 30.

PMID:
27365528
11.

CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.

Conroy MJ, Galvin KC, Kavanagh ME, Mongan AM, Doyle SL, Gilmartin N, O'Farrelly C, Reynolds JV, Lysaght J.

Immunol Cell Biol. 2016 Jul;94(6):531-7. doi: 10.1038/icb.2016.26. Epub 2016 Apr 5.

PMID:
27046081
12.

Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma.

Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O'Sullivan KE, Feighery R, MacCarthy F, O'Toole D, Ravi N, Reynolds JV, O'Sullivan J, Lysaght J.

Cancer Lett. 2016 Jan 1;370(1):117-24. doi: 10.1016/j.canlet.2015.10.019. Epub 2015 Oct 28.

PMID:
26519754
13.

Nanomedicine applied to translational oncology: A future perspective on cancer treatment.

Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A.

Nanomedicine. 2016 Jan;12(1):81-103. doi: 10.1016/j.nano.2015.08.006. Epub 2015 Sep 12. Review.

PMID:
26370707
14.

Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma.

Lynam-Lennon N, Connaughton R, Carr E, Mongan AM, O'Farrell NJ, Porter RK, Brennan L, Pidgeon GP, Lysaght J, Reynolds JV, O'Sullivan J.

BMC Cancer. 2014 Dec 3;14:907. doi: 10.1186/1471-2407-14-907.

15.

Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment.

Mockler MB, Conroy MJ, Lysaght J.

Front Oncol. 2014 May 16;4:107. doi: 10.3389/fonc.2014.00107. eCollection 2014. Review.

16.

The role of inflammation in cancer of the esophagus.

O'Sullivan KE, Phelan JJ, O'Hanlon C, Lysaght J, O'Sullivan JN, Reynolds JV.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):749-60. doi: 10.1586/17474124.2014.913478. Epub 2014 May 23. Review.

PMID:
24857183
17.

Combined influence of basal media and fibroblast growth factor on the expansion and differentiation capabilities of adipose-derived stem cells.

Ahearne M, Lysaght J, Lynch AP.

Cell Regen (Lond). 2014 Nov 26;3(1):13. doi: 10.1186/2045-9769-3-13. eCollection 2014.

18.

Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?

O'Sullivan KE, Reynolds JV, O'Hanlon C, O'Sullivan JN, Lysaght J.

J Gastrointest Cancer. 2014 Mar;45(1):1-11. doi: 10.1007/s12029-013-9555-x. Review.

PMID:
24163144
19.

The esophagitis to adenocarcinoma sequence; the role of inflammation.

Kavanagh ME, O'Sullivan KE, O'Hanlon C, O'Sullivan JN, Lysaght J, Reynolds JV.

Cancer Lett. 2014 Apr 10;345(2):182-9. doi: 10.1016/j.canlet.2013.08.017. Epub 2013 Aug 27. Review.

PMID:
23994342
20.

Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research.

Doyle SL, Bennett AM, Donohoe CL, Mongan AM, Howard JM, Lithander FE, Pidgeon GP, Reynolds JV, Lysaght J.

Nutr Res. 2013 Mar;33(3):171-9. doi: 10.1016/j.nutres.2012.12.007. Epub 2013 Jan 30.

PMID:
23507222
21.

Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis.

Allott EH, Morine MJ, Lysaght J, McGarrigle SA, Donohoe CL, Reynolds JV, Roche HM, Pidgeon GP.

Clin Transl Gastroenterol. 2012 Apr 19;3:e12. doi: 10.1038/ctg.2012.5.

22.

The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells.

Lysaght J, Verma NK, Maginn EN, Ryan JM, Campiani G, Zisterer DM, Williams DC, Browne PV, Lawler MP, McElligott AM.

Int J Oncol. 2013 Jan;42(1):239-46. doi: 10.3892/ijo.2012.1688. Epub 2012 Nov 6.

PMID:
23135704
23.

The SGBS cell strain as a model for the in vitro study of obesity and cancer.

Allott EH, Oliver E, Lysaght J, Gray SG, Reynolds JV, Roche HM, Pidgeon GP.

Clin Transl Oncol. 2012 Oct;14(10):774-82. doi: 10.1007/s12094-012-0863-6. Epub 2012 Aug 2.

PMID:
22855155
24.

Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma.

Donohoe CL, Doyle SL, McGarrigle S, Cathcart MC, Daly E, O'Grady A, Lysaght J, Pidgeon GP, Reynolds JV.

Br J Surg. 2012 Mar;99(3):387-96. doi: 10.1002/bjs.8658. Epub 2012 Jan 12.

PMID:
22241325
25.

IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.

Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J.

Am J Gastroenterol. 2012 Feb;107(2):196-204. doi: 10.1038/ajg.2011.417. Epub 2011 Dec 6.

PMID:
22146489
26.

Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.

Cathcart MC, Lysaght J, Pidgeon GP.

Cancer Metastasis Rev. 2011 Dec;30(3-4):363-85. doi: 10.1007/s10555-011-9324-x. Review.

PMID:
22134655
27.

MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.

Allott EH, Lysaght J, Cathcart MC, Donohoe CL, Cummins R, McGarrigle SA, Kay E, Reynolds JV, Pidgeon GP.

Mol Carcinog. 2013 Feb;52(2):144-54. doi: 10.1002/mc.21840. Epub 2011 Nov 28.

PMID:
22121096
28.

Visceral obesity, metabolic syndrome, insulin resistance and cancer.

Doyle SL, Donohoe CL, Lysaght J, Reynolds JV.

Proc Nutr Soc. 2012 Feb;71(1):181-9. doi: 10.1017/S002966511100320X. Epub 2011 Nov 3.

PMID:
22051112
29.

Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue.

Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM, McGarrigle SA, Ravi N, Reynolds JV, Pidgeon GP.

Cancer Lett. 2011 Dec 15;312(1):62-72. doi: 10.1016/j.canlet.2011.07.034. Epub 2011 Aug 11.

PMID:
21890265
30.

Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer.

Carroll PA, Healy L, Lysaght J, Boyle T, Reynolds JV, Kennedy MJ, Pidgeon G, Connolly EM.

Mol Carcinog. 2011 Aug;50(8):643-51. doi: 10.1002/mc.20764. Epub 2011 May 13.

PMID:
21574190
31.

T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma.

Lysaght J, Allott EH, Donohoe CL, Howard JM, Pidgeon GP, Reynolds JV.

Br J Surg. 2011 Jul;98(7):964-74. doi: 10.1002/bjs.7498. Epub 2011 Apr 21.

PMID:
21520028
32.

Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.

Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG.

Radiat Res. 2010 Dec;174(6):703-11. doi: 10.1667/RR2295.1. Epub 2010 Oct 4.

PMID:
21128793
33.

Obesity and gastrointestinal cancer.

Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV.

Br J Surg. 2010 May;97(5):628-42. doi: 10.1002/bjs.7079. Review.

PMID:
20306531
34.

Obesity and post-operative complications in patients undergoing non-bariatric surgery.

Doyle SL, Lysaght J, Reynolds JV.

Obes Rev. 2010 Dec;11(12):875-86. doi: 10.1111/j.1467-789X.2009.00700.x. Review.

PMID:
20025695
35.

Lipoxygenase metabolism: roles in tumor progression and survival.

Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, Honn KV.

Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24. Review.

PMID:
17943411
36.

Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity.

Lysaght J, Jarnicki AG, Mills KH.

Cancer Immunol Immunother. 2007 Sep;56(9):1367-79. Epub 2007 Feb 6.

PMID:
17279412
37.

Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1.

Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, Horne MK.

J Biol Chem. 2006 Oct 6;281(40):30152-65. Epub 2006 Jul 17. Retraction in: J Biol Chem. 2017 Jul 14;292(28):12007.

39.

Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.

Casey DG, Lysaght J, James T, Bateman A, Melcher AA, Todryk SM.

Immunology. 2003 Sep;110(1):105-11.

40.

Developments in cancer vaccination.

Lysaght J, Todryk S.

Curr Opin Investig Drugs. 2003 Jun;4(6):716-21. Review.

PMID:
12901231

Supplemental Content

Loading ...
Support Center